Eprontia - (25 mg/mL; Oral Solution)

Generic Name	Topiramate	Innovator	Cutis (Azurity)
Dosage	25 mg/mL; Oral Solution	Branded US Sales	Less Than $1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	None	Tentative Approvals	None
Final Approvals	Less Than 5	Generic Launches	None
Indication	EPRONTIA is indicated for: 1) Epilepsy: Initial monotherapy for the treatment of partial-onset or primary generalized tonic-clonic seizures in patients 2 years of age and older ; adjunctive therapy for the treatment of partial-onset seizures, primary generalized tonic-clonic seizures, or seizures associated with LennoxGastaut syndrome in patients 2 years of age and older. 2) Preventive treatment of migraine in patients 12 years of age and older.
Complexities	Yes

Executive Summary

Patent Status

Launch Timelines and Competition

Company	FTF Status / 180 days exclusivity	30-Months stay	Current Litigation Status	Current Approval Status	Likelihood of launch
*****	*** / ***	*** **, ****	*******	********	******* *** **** *** *** ****

Chronology Of Events